Skip to contents

Daniel Hal Solomon, MD, MPH
Chief, Section of Clinical Sciences, Brigham and Women's Hospital
Professor of Medicine, Harvard Medical School

Brigham and Women's Hospital
Department of Medicine
Rheumatology, Immunology
75 Francis Street
Boston, MA 02115

Research Email: dsolomon@partners.org

Edit Profile


Research Narrative:

Dr. Solomon is primarily a population scientist focusing on the epidemiology and health services of rheumatic disease. He serves as the Chief of the Section of Clinical Sciences in the Division of Rheumatology at BWH. His research work is primarily funded by the NIH, AHRQ, and foundations. He has served major roles at the American College of Rheumatology and within the osteoporosis community as well. Currently, Dr. Solomon spends 85% of his time on research and mentoring junior investigators, 5% on administrative responsibilities, and 10% on clinical care. His teaching is primarily through his research mentoring as well as Co-Directing the musculoskeletal pathophysiology course for Harvard Medical School-Massachusetts Institute of Technology HST program, which he did from 2017-2019. He also precepts in Rheumatology clinic and attends on the Rheumatology consult service. His achievements in population science research focuses on three areas. First, Dr. Solomon has been a leading investigator on the cardiovascular safety of nonsteroidal anti-inflammatory drugs (NSAIDs). He served on the Executive Committee of the PRECISION trial and has been the first author on 12 original articles in this area, has had several industry-sponsored grants and one AHRQ sponsored grant in this area. As well, he led the American College of Rheumatology Blue Ribbon Panel to set recommendations for NSAIDs. He has given over 15 invited talks on this topic and currently serves on the Executive Committee of the largest randomized controlled trial on the cardiovascular safety of NSAIDs and selective COX-2 inhibitors, on the DSMB of two RCTs in rheumatology, and as a consultant to the FDA on the Safety of Arthritis drugs. Second, Dr. Solomon has focused much of his research on cardiovascular manifestations of rheumatoid arthritis and its treatment. He completed one NIH grant on this topic and is the co-Principal Investigator on an NIH funded U01 studying cardiovascular disease in rheumatoid arthritis. This is a 35 site trial testing different treatment strategies and their effect on cardiovascular risk. He also recently developed a rheumatoid arthritis specific cardiovascular risk score. He is the first author on 6 publications describing the epidemiology of cardiovascular disease in patients with rheumatoid arthritis. He has given 15 invited lectures in this area. Finally, Dr Solomon has helped define standards for osteoporosis care improvement. He has received two NIH grants in this area. He recently completed an NIH funded large-scale adherence improvement trial for osteoporosis medications. He has first authored 8 original articles in this area. He has given 10 invited lectures on osteoporosis improvement. He currently serves on the Governing Committee of the National Bone Health Association, focusing on methods to improve dissemination of proven improvement methods. Dr. Solomon teaches and mentors primarily in rheumatic disease epidemiology and pharmacoepidemiology. He has mentored >40 fellows and trainees and has had a K24 award from NIH with 25% effort devoted to research training and mentoring. He developed and directed a course in clinical research for rheumatologists and is currently co-directing a similar course with longitudinal mentoring. He teaches residents in the BWH Department of Medicine’s lecture series and journal club. Dr. Solomon has played a prominent role in academic publishing in rheumatology. He has served on the editorial board of the premier American rheumatology journal, Arthritis & Rheumatology, for a decade, and he currently serves as the Editor in Chief. In these roles, he has an important impact on publication policy, strategy, and manuscript selection. In summary, Dr. Solomon is an expert in rheumatic disease epidemiology with a focus on drug safety and cardiovascular outcomes. He has demonstrated expertise in these areas with grants, papers, and lectures. As well, he has received funding to mentor rheumatologists in drug safety epidemiology. He plays leadership roles at BWH, at the ACR, and in relevant academic circles at Harvard.


Education:
Harvard School of Public Health, 1998, MPH
Yale School of Medicine, 1992, MD

Honors/Awards:
American College of Rheumatology Young Investigator Award
NIH Mentoring Award
Chief, Section of Clinical Sciences, Rheumatology
Co-Director, Patient-Centered Research Center